Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients

Giuseppe Derosa, A. F G Cicero, G. Murdolo, L. Ciccarelli, R. Fogari

Research output: Contribution to journalArticle

Abstract

Aim: The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese diabetic patients of both sexes, with specific attention to metabolic pattern-induced changes and cardiovascular effects. Methods: Patients were enrolled, evaluated, and followed in 3 Italian Centres of Internal Medicine. We evaluated 144 obese diabetic patients. All were required to have been diagnosed as being diabetic for at least 6 months, and had glycaemic control with diet alone or diet and oral hypoglycaemic agents. We administered orlistat (360 mg/d) or sibutramine (10 mg/d) in a randomized, controlled, double-blind clinical study, and evaluated anthropometric variables, glycaemic control, blood pressure and heart rate (HR) during 12 months of this treatment. Results: A total of 141 (69 males and 72 females; 35 males and 36 females, aged 53±5 yr with orlistat; 34 males and 36 females, aged 51±4 yr with sibutramine) completed the 4 weeks on controlled-energy diet and were randomized to double-blind treatment with orlistat (n=71) or sibutramine (n=70). Significant body mass index (BMI) improvement was present after 6 (p1c decrease was obtained after 6 (p

Original languageEnglish
Pages (from-to)222-229
Number of pages8
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume17
Issue number4
Publication statusPublished - Aug 2004

Fingerprint

sibutramine
glycemic control
Diet
diet
hypoglycemic agents
blood pressure
body mass index
heart rate
clinical trials
mouth
medicine
Therapeutics
Internal Medicine
Double-Blind Method
Hypoglycemic Agents
Body Mass Index
gender
Heart Rate
energy
Blood Pressure

Keywords

  • Diabetes mellitus
  • Obesity
  • Orlistat
  • Safety
  • Sibutramine
  • Type 2

ASJC Scopus subject areas

  • Food Science
  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. / Derosa, Giuseppe; Cicero, A. F G; Murdolo, G.; Ciccarelli, L.; Fogari, R.

In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 17, No. 4, 08.2004, p. 222-229.

Research output: Contribution to journalArticle

@article{c038eac4a9f14de18f6e0101bb475fd0,
title = "Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients",
abstract = "Aim: The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese diabetic patients of both sexes, with specific attention to metabolic pattern-induced changes and cardiovascular effects. Methods: Patients were enrolled, evaluated, and followed in 3 Italian Centres of Internal Medicine. We evaluated 144 obese diabetic patients. All were required to have been diagnosed as being diabetic for at least 6 months, and had glycaemic control with diet alone or diet and oral hypoglycaemic agents. We administered orlistat (360 mg/d) or sibutramine (10 mg/d) in a randomized, controlled, double-blind clinical study, and evaluated anthropometric variables, glycaemic control, blood pressure and heart rate (HR) during 12 months of this treatment. Results: A total of 141 (69 males and 72 females; 35 males and 36 females, aged 53±5 yr with orlistat; 34 males and 36 females, aged 51±4 yr with sibutramine) completed the 4 weeks on controlled-energy diet and were randomized to double-blind treatment with orlistat (n=71) or sibutramine (n=70). Significant body mass index (BMI) improvement was present after 6 (p1c decrease was obtained after 6 (p",
keywords = "Diabetes mellitus, Obesity, Orlistat, Safety, Sibutramine, Type 2",
author = "Giuseppe Derosa and Cicero, {A. F G} and G. Murdolo and L. Ciccarelli and R. Fogari",
year = "2004",
month = "8",
language = "English",
volume = "17",
pages = "222--229",
journal = "Diabetes, Nutrition and Metabolism - Clinical and Experimental",
issn = "0394-3402",
publisher = "Editrice Kurtis s.r.l.",
number = "4",

}

TY - JOUR

T1 - Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients

AU - Derosa, Giuseppe

AU - Cicero, A. F G

AU - Murdolo, G.

AU - Ciccarelli, L.

AU - Fogari, R.

PY - 2004/8

Y1 - 2004/8

N2 - Aim: The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese diabetic patients of both sexes, with specific attention to metabolic pattern-induced changes and cardiovascular effects. Methods: Patients were enrolled, evaluated, and followed in 3 Italian Centres of Internal Medicine. We evaluated 144 obese diabetic patients. All were required to have been diagnosed as being diabetic for at least 6 months, and had glycaemic control with diet alone or diet and oral hypoglycaemic agents. We administered orlistat (360 mg/d) or sibutramine (10 mg/d) in a randomized, controlled, double-blind clinical study, and evaluated anthropometric variables, glycaemic control, blood pressure and heart rate (HR) during 12 months of this treatment. Results: A total of 141 (69 males and 72 females; 35 males and 36 females, aged 53±5 yr with orlistat; 34 males and 36 females, aged 51±4 yr with sibutramine) completed the 4 weeks on controlled-energy diet and were randomized to double-blind treatment with orlistat (n=71) or sibutramine (n=70). Significant body mass index (BMI) improvement was present after 6 (p1c decrease was obtained after 6 (p

AB - Aim: The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese diabetic patients of both sexes, with specific attention to metabolic pattern-induced changes and cardiovascular effects. Methods: Patients were enrolled, evaluated, and followed in 3 Italian Centres of Internal Medicine. We evaluated 144 obese diabetic patients. All were required to have been diagnosed as being diabetic for at least 6 months, and had glycaemic control with diet alone or diet and oral hypoglycaemic agents. We administered orlistat (360 mg/d) or sibutramine (10 mg/d) in a randomized, controlled, double-blind clinical study, and evaluated anthropometric variables, glycaemic control, blood pressure and heart rate (HR) during 12 months of this treatment. Results: A total of 141 (69 males and 72 females; 35 males and 36 females, aged 53±5 yr with orlistat; 34 males and 36 females, aged 51±4 yr with sibutramine) completed the 4 weeks on controlled-energy diet and were randomized to double-blind treatment with orlistat (n=71) or sibutramine (n=70). Significant body mass index (BMI) improvement was present after 6 (p1c decrease was obtained after 6 (p

KW - Diabetes mellitus

KW - Obesity

KW - Orlistat

KW - Safety

KW - Sibutramine

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=8644223451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644223451&partnerID=8YFLogxK

M3 - Article

C2 - 15575343

AN - SCOPUS:8644223451

VL - 17

SP - 222

EP - 229

JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental

JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental

SN - 0394-3402

IS - 4

ER -